GlassScriptPhysician profile
Christopher L Bowlus
NPI 1942252085
$168,479.69
in general payments reported to CMS, 2019-2025
19 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13K · 2022: $6,553 · 2023: $27K · 2024: $90K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $80K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Travel and Lodging: $23K · Honoraria: $3,735 · Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $79,804.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,050.00 |
| Travel and Lodging | $23,460.27 |
| Honoraria | $3,735.00 |
| Food and Beverage | $1,572.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Innovation | $48,320.18 | 2024-2025 | Iqirvo |
| Ipsen Biopharmaceuticals, INC | $44,289.81 | 2023-2025 | Bylvay |
| Gilead Sciences, INC. | $27,040.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $22,810.70 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,545.00 | 2020 | |
| Amgen INC. | $4,800.00 | 2024 | Uplizna |
| Mirum Pharmaceuticals, INC. | $4,657.76 | 2023-2025 | Livmarli |
| Alnylam Pharmaceuticals INC. | $3,000.00 | 2024 | |
| Ipsen Bioscience INC. | $2,490.00 | 2024 | |
| Intercept Pharmaceuticals, INC. | $1,850.00 | 2020-2025 | |
| Eli Lilly and Company | $1,602.75 | 2020-2025 | |
| Astrazeneca Uk Limited | $805.50 | 2025 | |
| Perspectum Diagnostics LTD | $267.78 | 2023-2025 | Livermultiscan, Mrcp+ |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bowlus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.